Anteris Technologies Global Corp. is a structural heart company focused on designing, developing, and commercializing minimally invasive medical devices for heart valve disease. Its portfolio centers on transcatheter aortic valve replacement systems and related technologies intended to restore healthy heart function in patients with aortic stenosis. The company also works on complementary structural heart solutions, including specialized tissue materials and delivery systems that support precise implantation and procedural performance. Anteris Technologies Global Corp. serves the cardiovascular care market, where its products are used by physicians and cardiac specialists in treatment settings that require advanced device-based interventions. With operations spanning multiple regions, the company plays a role in the broader medical technology sector by addressing the needs of patients and clinicians seeking catheter-based alternatives for heart valve repair and replacement.
WebsiteToowong Tower
Toowong, QLD, 4066
Australia
Detailed price information for Anteris Technologies Global Corp (AVR-Q) from The Globe and Mail including charting and trades.
Detailed price information for Anteris Technologies Global Corp (AVR-Q) from The Globe and Mail including charting and trades.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has appointed experienced financial executive Brent Moen as chief financial officer, effective September 12, 2026 AEST. Moen brings more than 25 years of leadership experience across public and private companies, with expertise spanning...
MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Confere
Detailed price information for Anteris Technologies Global Corp (AVR-Q) from The Globe and Mail including charting and trades.
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. Q2 2026 Highlights Secured U.S. Medicare reimbursement eligibility for the global pivotal P
Investors talking about AVR also mention
What share of all stock conversation is about AVR?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% +0 | 0% 0 | 0% +0 |
Of the messages about AVR that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 0% -100 | 93.48% -6.52 | 95% +6.28 | 73.99% -2.71 | ||
| Bearish | 100% new | 6.52% +6.52 | 5% -6.28 | 26.01% +2.71 |
Of the messages about AVR that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 100% | 80.06% | ||
| Technical Analysis | — | 0% | 0% | 18.33% | ||
| Earnings | — | 0% | 0% | 0.96% | ||
| Analysts | — | 0% | 0% | 0.64% | ||
| Controversies | — | 0% | 0% | 0% | ||
| Macro | — | 0% | 0% | 0% |
Of the messages about AVR, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 40% | 54.35% | 58.47% | 11.23% | ||
| Newcomers | 60% | 45.65% | 41.53% | 88.77% |